Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and mutation.

Fiche publication

Date publication

août 2025

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria

Tous les auteurs :
Forschner J, Huynh J, Schroeder C, Armeanu-Ebinger S, Seibel-Kelemen O, Gschwind A, Bonzheim I, Eigentler TK, Amaral T, Ossowski S, Flatz L, Garbe C, Forschner A, Reitmajer M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40874224

Résumé

Immune checkpoint inhibitors (ICI) have significantly improved melanoma-specific survival (MSS), particularly in patients with tumors with a high tumor mutational burden (TMB) or mutation. In the adjuvant setting, ICIs significantly improve relapse-free survival (RFS), but data on MSS are still lacking. Tissue samples from 83 patients with stage IIIC/D/IV melanoma who started adjuvant ICI between March 2018 and September 2019 were examined using a 700 gene panel. TMB and mutation status were analyzed to determine their potential influence on RFS and MSS. TMB levels ≥ 20 Var/Mb were classified as TMB high, corresponding to the top 20% TMB levels in the cohort. RFS and MSS were significantly improved in patients whose tumors had high TMB levels and mutation (p<0.001 and p=0.002, respectively). Patients with -mutated tumors and high TMB seem to benefit particularly from adjuvant ICI.